Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

454.96 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

69 70 Next >

Market Whales and Their Recent Bets on VRTX Options ↗

January 17, 2024

Via Benzinga

Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5

January 17, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule ↗

January 17, 2024

FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the...

Via Benzinga

The Best Stock to Invest $1,000 in Right Now ↗

January 17, 2024

This stock has what it takes to be a big winner.

Via The Motley Fool

Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock ↗

January 16, 2024

Shares of Vertex have risen exponentially since last month. Crispr stock, though, is meandering.

Via Investor's Business Daily

Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals ↗

January 11, 2024

Via Benzinga

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 16 Analysts ↗

January 09, 2024

Via Benzinga

A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings ↗

January 09, 2024

Via Benzinga

Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

January 16, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 16, 2024

Via Benzinga

Here's Why CRISPR Therapeutics Stock Rose 54% Last Year ↗

January 15, 2024

Key regulatory developments sent this biotech stock higher.

Via The Motley Fool

Down 88%, Could Editas Medicine Be a Good Investment Now? ↗

January 15, 2024

The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.

Via The Motley Fool

$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today ↗

January 08, 2024

Via Benzinga

Is Vertex Pharmaceuticals Stock a Buy Now? ↗

January 06, 2024

The biotech's prospects keep improving.

Via The Motley Fool

My 3 Highest-Conviction Growth Stocks to Buy in 2024 ↗

January 14, 2024

Simply put, these stocks inspire confidence.

Via The Motley Fool

3 Growth Stocks to Buy That Could Be Massive Long-Term Winners ↗

January 14, 2024

These stocks appear to have what it takes to keep up their winning ways.

Via The Motley Fool

3 Unstoppable Stocks to Buy in 2024 ↗

January 13, 2024

These stocks appear to be on a clear path to continued growth.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week ↗

January 13, 2024

These companies could stand out thanks to game-changing technology.

Via The Motley Fool

Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' ↗

January 12, 2024

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. (NYSE: UBER) shares hit an all-time high on Thursda

Via Benzinga

3 Stocks to Buy in the Booming Field of Gene Editing ↗

January 11, 2024

As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.

Via InvestorPlace

Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)? ↗

January 11, 2024

Reasonable growth and debt and a high ROIC for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX).

Via Chartmill

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 10, 2024

Via Benzinga

2 Red Flags for Bluebird Bio Stock ↗

January 10, 2024

The biotech's struggles may continue.

Via The Motley Fool

These 3 Stocks Have Beaten the S&P Average Return for Years and Are Likely to Continue That Trend ↗

January 10, 2024

These winners seem likely to keep up their winning ways.

Via The Motley Fool

Topics Stocks

Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia

January 09, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

2 low-priced gene therapy stocks to speculate on

January 08, 2024

Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe

Via MarketBeat

5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday ↗

January 08, 2024

The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.

Via Benzinga

The Ultimate Growth Stock to Buy With $1,000 Right Now ↗

January 08, 2024

The stock, trading for about $60, has plenty of room to run.

Via The Motley Fool

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

January 07, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

5 Top Stocks to Buy in January ↗

January 07, 2024

Start the year off right by investing in these quality businesses.

Via The Motley Fool

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.